Characteristic | Subgroup | No. of patients | Percentage |
---|---|---|---|
Number of treatment cycles applied | 1 treatment cycle | 15/52 | 28.8 |
2 treatment cycles | 11/52 | 21.2 | |
3 treatment cycles | 5/52 | 9.6 | |
4 treatment cycles | 16/52 | 30.8 | |
5 treatment cycles | 1/52 | 1.9 | |
6 treatment cycles | 3/52 | 5.8 | |
7 treatment cycles | 1/52 | 1.9 | |
Systemic pretreatment prior to Lu-177-PSMA-617 radioligand therapy | Bicalutamide and/or Leuprorelin | 48/52 | 92.3 |
Enzalutamide and/or Abiraterone | 44/52 | 84.6 | |
Chemotherapy (Docetaxel or Cabazitaxel) | 39/52 | 75.0 | |
Ra-223-Dichloride | 8/52 | 15.4 | |
Local-regional pretreatment prior to Lu-177-PSMA-617 radioligand therapy | Radical prostatectomy | 33/52 | 63.5 |
External beam radiation and/or Brachytherapy | 39/52 | 75.0 | |
Location of metastases in pre-therapeutic Ga-68-PSMA-PET/CT scan | Skeletal | 52/52 | 100.0 |
Lymphatic | 42/52 | 80.8 | |
Hepatic | 9/52 | 17.3 | |
Cerebral | 3/52 | 5.8 | |
Pulmonary | 3/52 | 5.8 |
Median | Range | |
---|---|---|
Age at 1st treatment cycle | 72.1 years | 56.3–84.6 years |